The Centers for Medicare & Medicaid Services (CMS) has announced a significant decision affecting clinical laboratories, granting the Commission on Laboratory Accreditation (COLA) renewed deeming authority for the specialty of Histocompatibility. This notice, published in the Federal Register on June 10, 2026, confirms COLA's approval for a five-year period, commencing July 10, 2026, and extending to June 10, 2031. This development is crucial for laboratories specializing in histocompatibility testing, as it allows those accredited by COLA to be recognized as compliant with federal Clinical Laboratory Improvement Amendments (CLIA) requirements without routine state inspections.
Understanding CLIA and Deeming Authority
The Clinical Laboratory Improvement Amendments of 1988 (CLIA) represent a cornerstone of federal oversight for laboratory testing in the United States. Enacted to ensure the accuracy, reliability, and timeliness of patient test results regardless of where the tests were performed. CLIA mandates federal standards for all laboratories conducting tests on human specimens for health assessment or to diagnose, prevent, or treat disease. A key provision within CLIA allows CMS to approve private, nonprofit accreditation organizations to "deem" laboratories compliant with CLIA requirements. This "deeming authority" means that if a laboratory is accredited by an approved organization, it is generally considered to meet CLIA standards, thereby streamlining the regulatory process and often reducing the need for direct federal or state inspections. CMS exercises rigorous scrutiny when evaluating such applications, ensuring that the accreditation body's standards are equivalent to or exceed the federal benchmarks outlined in 42 CFR part 493.
COLA's Approval for Histocompatibility
The recent Federal Register notice specifically highlights CMS's determination that COLA meets or exceeds the applicable CLIA requirements for the specialty of Histocompatibility. Histocompatibility testing, often referred to as Human Leukocyte Antigen or HLA typing, is a highly specialized field critical for organ and tissue transplantation, transfusion medicine, and certain disease associations. The precision and accuracy of these tests directly impact patient safety and successful medical outcomes.
CMS conducted a thorough review of COLA's initial application and subsequent submissions. This evaluation confirmed that COLA's accreditation program adequately addresses key areas of laboratory operation. Specifically, CMS found COLA's requirements to be equal to or more stringent than CLIA standards across several critical subparts of 42 CFR part 493. These include Subpart E, which governs accreditation by private organizations; Subpart J, covering facility administration for nonwaived testing; Subpart K, related to the quality system for nonwaived testing; Subpart M, concerning personnel requirements for nonwaived testing; Subpart Q, which details inspection processes; and Subpart R, outlining enforcement procedures as they apply to accreditation organizations. This comprehensive assessment underscores CMS's confidence in COLA's ability to ensure its accredited laboratories maintain high operational and quality standards.
Implications for Clinical Laboratories
For clinical laboratories specializing in histocompatibility, COLA's renewed deeming authority offers a clear pathway to demonstrating CLIA compliance. Laboratories accredited by COLA during the approved five-year period will generally be exempt from routine compliance inspections by state survey agencies. This can translate into reduced administrative burden and potentially more predictable regulatory oversight.
However, this exemption does not signify a complete absence of federal scrutiny. The Federal Register notice explicitly states that accredited laboratories remain subject to validation and complaint investigation surveys performed by CMS or its designated agents. These federal validation inspections may be conducted on a representative sample basis or in response to substantial allegations of noncompliance. This ongoing federal monitoring serves as a crucial safeguard, verifying that COLA-accredited laboratories consistently adhere to CLIA requirements and that COLA's oversight mechanisms remain effective.
Federal Validation and Continuing Oversight
CMS's approval of COLA is contingent on a robust system of continuing oversight. The agency retains the authority to monitor COLA itself and to conduct direct validation inspections of COLA-accredited laboratories. This dual-layered approach ensures accountability at both the accreditation organization level and the individual laboratory level.
The CLIA regulations at 42 CFR 493.575 empower CMS to withdraw approval from an accreditation organization if it fails to maintain standards equal to or more stringent than CLIA requirements, or if systemic problems are identified in its monitoring, inspection, or enforcement processes. In such cases, CMS may impose a probationary period, typically not exceeding one year, to allow the organization to rectify identified issues. Failure to address these concerns could ultimately lead to the withdrawal of deeming authority, an action that would be publicly announced in the Federal Register, detailing the reasons for removal. This framework underscores the federal government's commitment to maintaining stringent quality controls in clinical laboratory testing, even when leveraging private accreditation bodies for compliance assurance.
